Is ALXA a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,229 people get ALXA articles and Market Currents by email alert.

Get email alerts on ALXA »

HEADLINES:

Alexza Pharmaceuticals Has A Partner In Big Pharma, Now What?
Bio Matt • Wed, May 15 • 19 Comments
Alexza Pharmaceuticals: A Teva Partnership Of Immense Meaning
Avi Greenberg • Wed, May 15 • 20 Comments
Alexza Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 14 • 1 Comment
Alexza Pharmaceuticals Inc. - Special Call
Wed, May 8
Alexza Announces Conference Call to Discuss Agreement with Teva to Market ADASUVE® in the U.S.

PR Newswire (May 8, 2013)
Teva and Alexza Announce Teva's License to Market ADASUVE® in the U.S.

PR Newswire (May 8, 2013)
Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy

PR Newswire (May 6, 2013)
Update: Alexza to Report 2013 First Quarter Financial Results on Tuesday, May 14, 2013

PR Newswire (May 1, 2013)
Alexza to Report 2013 First Quarter Financial Results on Thursday, May 9, 2013

PR Newswire (Apr 22, 2013)
XenoPort: A High Probablity Run-Up Trade
bsiflingtrades • Thu, Apr 18 • 5 Comments
Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
3 Biotechs With Upcoming Product Launches
Markus Aarnio • Thu, Apr 11 • 9 Comments
Alexza Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 26 • 1 Comment
Alexza Reports 2012 Fourth Quarter and Full Year Financial Results

PR Newswire (Mar 26, 2013)
Solving The R&D Investment Dilemma With Project Funding: Mark Kessel
Life Sciences Report • Sun, Mar 24 • 1 Comment
Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer

PR Newswire (Mar 13, 2013)
Alexza to Report 2012 Year-End Financial Results on Tuesday, March 26, 2013

PR Newswire (Mar 6, 2013)
Why Alexza Pharmaceuticals Ran 10% In 5 Minutes
Bio Matt • Wed, Mar 6 • 17 Comments
Alexza Pharmaceuticals' Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences

PR Newswire (Feb 25, 2013)
Alexza Receives Marketing Authorization for ADASUVE® (Staccato® Loxapine) in the European Union

PR Newswire (Feb 21, 2013)

To learn more about Seeking Alpha Pro, click here.

Alexza Pharmaceuticals Has A Partner In Big Pharma, Now What?
Bio Matt • Wed, May 15 • 19 Comments
Alexza Pharmaceuticals: A Teva Partnership Of Immense Meaning
Avi Greenberg • Wed, May 15 • 20 Comments
Why Alexza Pharmaceuticals Ran 10% In 5 Minutes
Bio Matt • Wed, Mar 6 • 17 Comments
Value Of Alexza's Staccato Platform Following Adasuve Approval
Richard Daifuku • Tue, Dec 25, 2012 • 10 Comments
Alexza: Maybe A Little Speculation Is Warranted
Rx Stocks • Thu, Dec 20, 2012 • 14 Comments
Roth Capital Expects FDA Approval For Alexza's Adasuve
Ben Yoffe • Thu, Dec 20, 2012 • 5 Comments
Winding Down 2012 With Last-Minute Bets On Alexza
Brian L. Wilson • Fri, Dec 14, 2012 • 9 Comments
Alexza Remains Meaningfully Undervalued
Biotech Sage • Wed, Dec 12, 2012 • 7 Comments
Alexza's Adasuve May Not Be Ready For FDA Approval
Beacon VP Investments • Tue, Dec 11, 2012 • 28 Comments
Alexza Is Meaningfully Overvalued Following Its Latest Rally
PropThink • Wed, Dec 5, 2012 • 62 Comments
Alexza Poised For Run-Up Into December U.S., EU Approval Decisions
Mike Havrilla • Wed, Sep 5, 2012 • 7 Comments
Will Alexza's Third Time Be The Charm?
Brian L. Wilson • Wed, Sep 5, 2012 • 2 Comments
Latest Bio Buzz Catalyst Trade: Alexza Pharmaceuticals
bsiflingtrades • Thu, Aug 23, 2012 • 6 Comments
Alexza Pharmaceuticals Reiterated With An Outperform At JMP Securities
Ben Yoffe • Fri, Aug 10, 2012 • 10 Comments
WBB Securities Recommends Alexza Pharmaceuticals As A Strong Buy
Ben Yoffe • Fri, Aug 3, 2012 • 5 Comments
Alexza's CEO Has High Expectations Of Receiving FDA Approval For Adasuve
Ben Yoffe • Mon, Jul 30, 2012 • 2 Comments
Pivotal FDA Decision Upcoming For Alexza
Jason Napodano • Wed, Apr 11, 2012 • 16 Comments
Alexza Pharmaceuticals: Forward Looking Approval Catalyst In Play
M. E. Garza • Wed, Dec 14, 2011
Alexza Pharmaceuticals: Is It A 'Dead Cat' Bounce If The Cat's Still Breathing?
M. E. Garza • Fri, Dec 9, 2011
Alexza's Agitation Drug Back Under Review - Trade the Upcoming Catalysts
Jason Napodano • Tue, Aug 9, 2011 • 3 Comments

XenoPort: A High Probablity Run-Up Trade
bsiflingtrades • Thu, Apr 18 • 5 Comments
Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
3 Biotechs With Upcoming Product Launches
Markus Aarnio • Thu, Apr 11 • 9 Comments
Solving The R&D Investment Dilemma With Project Funding: Mark Kessel
Life Sciences Report • Sun, Mar 24 • 1 Comment
MAP's Levadex Ready For FDA Approval
Beacon VP Investments • Sun, Feb 3 • 10 Comments
FDA Decision On MAP's Levadex Approaching, Stock Starting To Reflect Optimism
PropThink • Thu, Jan 10 • 13 Comments
Drug Approvals Are Priced In, Wait For The Buying Opportunity
Rx Stocks • Mon, Dec 24, 2012 • 9 Comments
This Week's Biotech Summary (December 16-21, 2012)
Ryan's View • Wed, Dec 19, 2012 • 9 Comments
Weekly Biotech Recap: Anticipation, Divergence
Brian L. Wilson • Mon, Dec 17, 2012 • 6 Comments
Selling FDA Approvals: Latest Results
BinaryLeverage • Thu, Dec 13, 2012 • 14 Comments
Friday's Small Cap Biopharma Catalyst Trade And Speculation Investment List
Scott Matusow • Fri, Nov 30, 2012 • 23 Comments
Biotech Weekend Recap: Short Week, Major Rally
Brian L. Wilson • Sun, Nov 25, 2012 • 10 Comments
Promising Biotech Stocks With Upcoming FDA Catalysts
David Zanoni • Tue, Nov 13, 2012 • 3 Comments
Using Options To Benefit From The Binary Nature Of FDA Decisions
David Anber • Thu, Oct 18, 2012
BioPharma Stock Movers For Wednesday, August 29
Scott Matusow • Wed, Aug 29, 2012 • 15 Comments
5 Pharmaceutical Companies With EMA Or MHRA Catalysts This Year
Markus Aarnio • Tue, Aug 28, 2012 • 6 Comments
Thursday's Bio-Pharma Drug Approval And Catalyst Event List
Scott Matusow • Thu, May 3, 2012 • 5 Comments
4 Healthcare Stocks Breaking Out Mid-Week
Timeless Wealth • Thu, May 3, 2012
12 Healthcare Companies Expecting May Catalysts
Spencer Knight • Tue, May 1, 2012 • 9 Comments
Biotech-Focused Star Hedge Fund Tang Capital's Q1 2012 Picks In Its $429 Million Portfolio
GuruFundPicks • Thu, Apr 26, 2012 • 4 Comments

Alexza Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 14 • 1 Comment
Alexza Pharmaceuticals Inc. - Special Call
Wed, May 8
Alexza Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 26 • 1 Comment
Alexza Pharmaceuticals' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Nov 6, 2012
Alexza Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Fri, Aug 10, 2012
Alexza Pharmaceuticals, Inc., Q3 2009 Earnings Call Transcript
Mon, Nov 9, 2009
Alexza Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript
Tue, Mar 10, 2009
Alexza Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
Tue, Nov 18, 2008
Alexza Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Tue, Sep 2, 2008
Alexza Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Mon, May 12, 2008
Alexza Pharmaceuticals, Inc.Q4 2007 Earnings Call Transcript
Mon, Mar 17, 2008

Alexza Announces Conference Call to Discuss Agreement with Teva to Market ADASUVE® in the U.S.

PR Newswire (May 8, 2013)
Teva and Alexza Announce Teva's License to Market ADASUVE® in the U.S.

PR Newswire (May 8, 2013)
Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy

PR Newswire (May 6, 2013)
Update: Alexza to Report 2013 First Quarter Financial Results on Tuesday, May 14, 2013

PR Newswire (May 1, 2013)
Alexza to Report 2013 First Quarter Financial Results on Thursday, May 9, 2013

PR Newswire (Apr 22, 2013)
Alexza Reports 2012 Fourth Quarter and Full Year Financial Results

PR Newswire (Mar 26, 2013)
Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer

PR Newswire (Mar 13, 2013)
Alexza to Report 2012 Year-End Financial Results on Tuesday, March 26, 2013

PR Newswire (Mar 6, 2013)
Alexza Pharmaceuticals' Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences

PR Newswire (Feb 25, 2013)
Alexza Receives Marketing Authorization for ADASUVE® (Staccato® Loxapine) in the European Union

PR Newswire (Feb 21, 2013)
Alexza Pharmaceuticals Appoints J. Kevin Buchi to its Board of Directors

PR Newswire (Jan 3, 2013)
Movers & Shakers: Monday’s biggest gaining and declining stocks

at MarketWatch.com (Dec 24, 2012)
Stocks to Watch: Stocks to watch Monday: RIM, Nike, Alexza

at MarketWatch.com (Dec 24, 2012)
After Hours: RIM shares extend losses in after-hours trading

at MarketWatch.com (Dec 21, 2012)
U.S. FDA Approves Alexza's ADASUVE® (loxapine) Inhalation Powder for the Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I Disorder in Adults

PR Newswire (Dec 21, 2012)
The CHMP Delivers a Positive Opinion Recommending Grant of Marketing Authorization for ADASUVE® (Staccato® Loxapine) in the European Union

PR Newswire (Dec 14, 2012)
Alexza Pharmaceuticals Receives Updated Day 180 List of Outstanding Issues for ADASUVE™ (Staccato® Loxapine) MAA

PR Newswire (Nov 19, 2012)
Alexza Reports 2012 Third Quarter Financial Results and Provides Business Update

PR Newswire (Nov 6, 2012)
Alexza Pharmaceuticals' Staccato® Technology Receives Frost & Sullivan Enabling Technology Award

PR Newswire (Oct 18, 2012)
Alexza Announces Third Quarter 2012 Financial Results Teleconference and Webcast

PR Newswire (Oct 17, 2012)

ALXA vs. ETF Alternatives

Company Description

We are a pharmaceutical company focused on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS, conditions. All of our product candidates are based on our proprietary technology, the Staccato system. The... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 15, 6:32 AM Alexza Pharmaceuticals (ALXA): Q1 EPS of -$1.31 misses by $0.86. Revenue of $729K beats by $271M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, May 8, 12:53 PM Midday top 10 gainers: TRMD +68%. SYNM +35%. AFFY +35%. ALXA +25%. CSPI +21%. PSE +21%. NBG +20%. WBMD +18%. SCOK +17%. EA +16%.
Midday top 10 losers: FIO -25%. OCLR -23%. LIOX -18%. VCLK -17%. AXLL -16%. OCLS -15%. BTH -15%. SALM -13%. ACFC -12%. SNTA -12%. Comment! [On the Move]
Wednesday, May 8, 9:17 AM Premarket gainers: ALXA +51%. PSE +19%. LEDR +16%. NBG +11%. WFM +8%. EA +6%. PRTS +6%. SFUN +6%. CTSH +5%.
Losers: FIO -22%. VCLK -19%. OCLR -19%. AXLL -9%. CIE -7%. CHRW -7%. SODA -6%. DDD -6%. SYMC -5%. Z -5%. VVUS -5%. Comment! [On the Move]
Wednesday, May 8, 9:11 AM Alexza Pharmaceuticals (ALXA) comes off trading halt, now up 52% premarket following the license deal with Teva (TEVA +0.3% premarket). The conference call discussing the matter is underway. 3 Comments [Breaking News, Healthcare, On the Move]
Wednesday, May 8, 9:00 AM Alexza Pharmaceuticals (ALXA) announces an exclusive U.S. license deal for Adasuve with Teva Pharmaceutical (TEVA). Nice deal for Alexza - it will receive an upfront payment of $40M with eligibility for another $195M based on milestones. Conference call to discuss is about to begin. Shares remains halted. (PR) Comment! [Healthcare, Breaking News]
Wednesday, May 8, 8:31 AM Alexza Pharmaceuticals (ALXA) is halted from trading with news pending. Comment! [Breaking News, Healthcare]
Wednesday, April 3, 11:03 AM Alexza Pharmaceuticals (ALXA +4%) gives back a little but remains firmly in the green following a +7% run-up during the pre-open session on an earlier upgrade from Piper Jaffray to Overweight. Piper notes that it's channel checks with ER physicians, psychiatrists, and opinion leaders was even more encouraging than it expected on both the near and longer-term market potential for Adasuve versus previous projections. Additionally, it's clinical attributes bode well for a value-added partnership being signed soon to enable effective launch in Q3. 1 Comment [Healthcare, On the Move]
Wednesday, April 3, 9:25 AM Alexza Pharmaceuticals (ALXA) is trading higher before the bell after Piper Jaffray upgrades the stock to Overweight from Neutral. Shares +7.3% premarket. 1 Comment [Healthcare]
Wednesday, April 3, 9:10 AM Premarket gainers: CALL +14%. CONN +10%. ZNGA +10%. ASTX +10%. UNXL +9%. AWRE +9%. OMPI +9%. NVAX +9%. ALXA +8%. MHR +7%. NFX +6%.
Losers: MSPD -19%. GPN -7%. 3 Comments [On the Move]
Tuesday, March 26, 5:44 PM More on Alexza Pharmaceuticals (ALXA): Q4 EPS misses expectations, with revenues coming at $729K, well below estimates of $3.48M. In the same period last year, the company reported a loss per share of $1.34 on revenues of $1.88M. R&D expenses were lower for the quarter, largely as a result of the suspension of development of AZ-007 and Staccato nicotine product candidates starting in late 2011, as well as efforts to conserve cash. Comment! [Healthcare, Earnings]
Tuesday, March 26, 5:15 PM Alexza Pharmaceuticals (ALXA): Q4 EPS of -$0.65. Revenue of $729K. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Thursday, February 21, 9:41 AM The EU approves Alexza Pharmaceuticals' (ALXA +2.2%) Adasuve, a treatment for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. The authorization adds to FDA backing. Alexza plans to launch Adasuve in the U.S. and EU in Q3. (PR) 1 Comment [Healthcare]
Thursday, February 21, 9:10 AM Premarket gainers: PRKR +38%. RPRX +31%. NVGN +28%. BRY +22%. PEGA +17%. LOCK +7%. LNCO +5%. ALXA +5%.
Losers: GENT -37%. PAY -34%. GFI -17%. ALU -7%. WLT -6%. TSLA -5%. Comment! [On the Move]
Monday, December 24, 2012, 2:57 PM After-hours top gainers, as of 2:30 p.m.: TVIX +3.6%. UVXY +3.1%. VXX +1.9%. SE +1.6%. ALXA +1.6%.
After-hours top losers: UGAZ -2.1%. XIV -1.7%. SVXY -1.7%. AIG -1.6%. ABB -1.3%. Comment! [On the Move]
Monday, December 24, 2012, 11:15 AM Midday top 10 gainers: ATV +34%. CT +18%. ALIM +12%. CLSN +12%. EJ +11%. EDAP +11%. GSS +11%. RGLS +10%. AVEO +10%. EGLE +10%.
Top 10 Losers: MHH -30%. TLAB -27%. ALXA -14%. XRTX -12%. AMPL -11%. CIG -10%. SVA -9%. ISS -9%. MITL -8%. RPTP -8%. 1 Comment [On the Move]
Monday, December 24, 2012, 9:10 AM Premarket Losers: TLAB -26%. ALXA -11%. Comment! [On the Move]

Ryan Mallory
Fuinhaz Setups for May 15 2013 | $ACAD $ALXA $CETV $CSIQ $SCTY $SODA $SPU | SharePlanner http://bit.ly/13xbTQb
Wed, 9:20 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

anomaly1
$ALXA strong buy $4.88
May 9, 4:02 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Perkins Cove
$ALXA (halted)....http://bit.ly/YF44In
May 8, 8:45 AM
Reply (3)

• !Report Abuse
View all 3 replies
Perkins Cove: Ohhh...yah.....up 45% to $6.30+ ....congrats ALXA holders. Anybody here get that nice jump?
May 8, 9:07 AM
• !Report Abuse
Perkins Cove: Oops, now $6.70. I should have jumped in....
May 8, 9:21 AM
• !Report Abuse
Add a reply...

140 characters

Bio Matt
Current biotech/pharma portfolio: $ALXA $SRPT $AMBS $GALE $ONCS $RAFA $MRK
Apr 13, 8:12 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jason F
Nothing Bullish About $ALXA stock chart. Really bearish chart. http://bit.ly/WOKzrE (analysis in the link)
12/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

JMEaramn
$ALXA What're the chances of this rebounding like EXEL?
12/23/12
Reply (1)

• !Report Abuse
View all 1 replies
JMattius: $EXEL rebounded? What was pre FDA approval price and what is it today? I would not call that a rebound.
12/23/12
• !Report Abuse
Add a reply...

140 characters

emeickhoff
I think its halted to prevent the short sellers to destroy the price on approval. This is a good sign $ALXA
12/23/12
Reply (1)

• !Report Abuse
View all 1 replies
JMattius: Take a look at $EXEL. Halted AH and sold off same AH and several sessions after. It is much lower than pre-approval price. Sell the news..
12/23/12
• !Report Abuse
Add a reply...

140 characters

Nick Zheng
$ALXA
12/22/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jason F
My $ALXA Run Down Targets -Chart Analysis - http://bit.ly/XWgkhe (On the site I posted a chart saying yesterday was time to sell)
12/21/12
Reply (1)

• !Report Abuse
View all 1 replies
Jason F: I think on one of the articles or stocktalks yesterday I wrote time to sell ALXA. The TA on the chart provided warning signs.
12/21/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Live level 2 after hours $ALXA now @ http://bit.ly/wJZkqa
12/21/12
Reply (13)

• !Report Abuse
View all 13 replies
GVT: Scott - Are you still holding ARQL ?
Jan 8, 1:56 PM
• !Report Abuse
amitschele: Scott . ARQL thoughts.
Jan 9, 12:37 PM
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Perkins Cove
$ALXA (halted)....http://bit.ly/YF44In
May 8, 8:45 AM
Reply (3)

• !Report Abuse
View all 3 replies
Perkins Cove: Ohhh...yah.....up 45% to $6.30+ ....congrats ALXA holders. Anybody here get that nice jump?
May 8, 9:07 AM
• !Report Abuse
Perkins Cove: Oops, now $6.70. I should have jumped in....
May 8, 9:21 AM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Live level 2 after hours $ALXA now @ http://bit.ly/wJZkqa
12/21/12
Reply (13)

• !Report Abuse
View all 13 replies
GVT: Scott - Are you still holding ARQL ?
Jan 8, 1:56 PM
• !Report Abuse
amitschele: Scott . ARQL thoughts.
Jan 9, 12:37 PM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$ALXA is my next catalyst pick http://seekingalpha.com/a/m0ch
11/28/12
Reply (5)

• !Report Abuse
View all 5 replies
Scott Matusow: Zacks analyst wrote a negative piece which I find to be partly disingenuous.
12/5/12
• !Report Abuse
u681694: Scott - what's your opinion on where ALXA is heading over the short - medium term?
12/28/12
• !Report Abuse
Add a reply...

140 characters

JMEaramn
$ALXA What're the chances of this rebounding like EXEL?
12/23/12
Reply (1)

• !Report Abuse
View all 1 replies
JMattius: $EXEL rebounded? What was pre FDA approval price and what is it today? I would not call that a rebound.
12/23/12
• !Report Abuse
Add a reply...

140 characters

emeickhoff
I think its halted to prevent the short sellers to destroy the price on approval. This is a good sign $ALXA
12/23/12
Reply (1)

• !Report Abuse
View all 1 replies
JMattius: Take a look at $EXEL. Halted AH and sold off same AH and several sessions after. It is much lower than pre-approval price. Sell the news..
12/23/12
• !Report Abuse
Add a reply...

140 characters

medic11
So when is this $ALXA deal going down? After hours? Let the big boys pull out their profits?
12/21/12
Reply (6)

• !Report Abuse
View all 6 replies
medic11: Same s@#t, different pile. Stock is down post approval. Just like AMRN.
12/22/12
• !Report Abuse
JMEaramn: Any ballparks as to how the restrictions are going to affect the stock price?
12/23/12
• !Report Abuse
Add a reply...

140 characters

Jason F
My $ALXA Run Down Targets -Chart Analysis - http://bit.ly/XWgkhe (On the site I posted a chart saying yesterday was time to sell)
12/21/12
Reply (1)

• !Report Abuse
View all 1 replies
Jason F: I think on one of the articles or stocktalks yesterday I wrote time to sell ALXA. The TA on the chart provided warning signs.
12/21/12
• !Report Abuse
Add a reply...

140 characters

9146fan
$ALXA has somebody caught short big time.
12/13/12
Reply (3)

• !Report Abuse
View all 3 replies
foldholder: why is the stock moving down today? how higher will it reach by 21st?
12/17/12
• !Report Abuse
JMattius: No FDA news until Friday so I expect a bit of a slow bleed leading up to Friday. Weak hands may be selling as well.
12/17/12
• !Report Abuse
Add a reply...

140 characters

reachmygoals1
$ALXA has chances to go 2 for 2 this month-Eu decision & FDA decision.Last month, manufacturing facility was inspected and satisfactory.
12/10/12
Reply (3)

• !Report Abuse
View all 3 replies
foldholder: $ALXA has a new article http://seekingalpha.com/a/mohd. Does it still make sense to buy this stock?
12/11/12
• !Report Abuse
JMattius: Buy if you feel it will get approved. Sell or stay away if you don't. No article can predict what the FDA is going to do.
12/11/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
Check out upcoming Fda approval Dates http://bit.ly/H6kqQR $ARNA, $RGEN, $XNPT, $SLXP, $GILD, $ALXA, $PLX,$VVUS, $AMGN,$FURX,$CTIC,$VRTX
4/1/12
Reply (3)

• !Report Abuse
View all 3 replies
freefdawatchlist: don't buy more, because if fda delay it by 3 month, the stock may drop. Check out other stock which haven't rallied up till now.
4/1/12
• !Report Abuse
phemale60: VVUS's Avanafil up for FDA approval late April also. Any info about it? I appreciate your insight!
4/1/12
• !Report Abuse
Add a reply...

140 characters

ALXA Alexza Pharmaceuticals, Inc.

ALXA

Alexza Pharmaceuticals, Inc.